At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 688 enrolled
Drug / intervention
CD5024 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.
In Brief
A Phase 3 clinical trial evaluating CD5024 and Azelaic acid 15% Gel for Papulopustular Rosacea. Completed, enrolled 688 participants across 50 sites in 2 countries.
Detailed Summary
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPapulopustular Rosacea
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionAug 2013
TodayJul 2026
First PostedDec 19, 2011
Enrollment StartDec 1, 2011
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 14.5 years ago
Interventions
CD5024drug
CD5024 1% Cream, once daily
Azelaic acid 15% Geldrug
Topical Gel applied twice daily